Abstract
INTRODUCTION
The Boston criteria v2.0 for cerebral amyloid angiopathy (CAA) incorporated non-hemorrhagic imaging markers. Their prevalence and significance in patients with cognitive impairment remain uncertain.
METHODS
We studied 622 memory clinic patients with available magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers. Two raters assessed non-hemorrhagic markers, and we explored their association with clinical characteristics through multivariate analyses.
RESULTS
Most patients had mild cognitive impairment; median age was 71 years and 50% were female. Using the v2.0 criteria, possible or probable CAA increased from 75 to 383 patients. Sixty-eight percent of the sample had non-hemorrhagic CAA markers, which were independently associated with age (odds ratio [OR] = 1.04, 95% confidence interval [CI] = 1.01–1.07), female sex (OR = 1.68, 95% CI = 1.11–2.54), and hemorrhagic CAA markers (OR = 2.11, 95% CI = 1.02–4.35).
DISCUSSION
Two-thirds of patients from a memory clinic cohort had non-hemorrhagic CAA markers, increasing the number of patients meeting the v2.0 CAA criteria. Longitudinal approaches should explore the implications of these markers, particularly the hemorrhagic risk in this population.
Highlights
The updated Boston criteria for cerebral amyloid angiopathy (CAA) now include non-hemorrhagic markers.
The prevalence of non-hemorrhagic CAA markers in memory clinic patients is unknown.
Two-thirds of patients in our memory clinic presented non-hemorrhagic CAA markers.
The presence of these markers was associated with age, female sex, and hemorrhagic CAA markers.
The hemorrhagic risk of patients presenting these type of markers remains unclear.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Ana Sofia Costa,
Milena Albrecht,
Arno Reich,
Omid Nikoubashman,
Jörg B. Schulz,
Kathrin Reetz,
João Pinho | June 13, 2024